Ionis Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
IONS Key Statistics
IONS News
Ionis Pharmaceuticals recently achieved key milestones with FDA approvals and launches of RNA-targeted drugs such as DAWNZERA and Tryngolza, while delivering a...
If you are watching Ionis Pharmaceuticals and trying to decide your next move, you are definitely not alone. There has been a flurry of interest lately, with th...
JP Morgan upgraded Ionis Pharmaceuticals (NASDAQ:IONS) to overweight from neutral citing a potential label expansion for Tryngolza (olezarsen) and promising can...
Analyst ratings
74%
of 27 ratingsMore IONS News
Ionis Pharmaceuticals (IONS) guided to north of $5 billion in peak sales for its current programs on Tuesday. Early Wednesday, Ionis stock was approaching a six...
Analyst Joseph Stringer of Needham maintained a Buy rating on Ionis Pharmaceuticals, boosting the price target to $78.00. Elevate Your Investing Strategy: Take...
Oppenheimer analyst Justin Kim raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $84 and keeps an Outperform rating on the shares. The...
In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $83.00....
J.P. Morgan analyst Jessica Fye upgraded the rating on Ionis Pharmaceuticals to a Buy today, setting a price target of $80.00. Elevate Your Investing Strategy:...